

What science can do

AstraZeneca Development Pipeline as at 10 February 2022



References to Notes and page numbers, and capitalised terms not defined in this supplement can be found in AstraZeneca's Annual Report and Form 20-F Information 2021 at www.astrazeneca.com/annualreport2021.

AstraZeneca-sponsored or -directed trial





New Molecular Entities (NMEs) and significant indications

Regulatory submission dates shown for assets in Phase III and beyond. As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Phase I

Compound	Mechanism		Area Under Investigation
Oncology			
AZD0466	BCL2/xL		haematological malignancies
AZD1390	ATM inhibitor		glioblastoma
AZD2936	PD1/TIGIT bispecific mAb		solid tumours
AZD4573	CDK9 inhibitor		haematological malignancies
AZD5991	MCL1 inhibitor		haematological malignancies
AZD7648	DNAPK		haematological and solid tumours
AZD7789	PD1/TIM3 bispecific mAb		solid tumours
AZD8205	B7-H4 TOP1i ADC		solid tumours
AZD8701 +/- <i>Imfinzi</i>	FOXP3 +/- PD-L1		solid tumours
<i>Imfinzi</i> + adavosertib	PD-L1 mAb + Wee1 inhibitor		solid tumours
IPH5201	CD39		solid tumours
MEDI1191	IL12 mRNA		solid tumours
MEDI5752 + Lenvatinib	PD-1/CTLA-4 bispecific mAb + VEGF		advanced renal cell carcinoma
MEDI9253	rNDV IL12		solid tumours
<i>Tagrisso</i> + (<i>Koselugo</i> or savolitinib) TATTON	EGFR inhibitor + (MEK inhibitor or MET inhibitor)		advanced EGFRm non-small cell lung cancer
CVRM			
AZD2373	Podocyte health		nephropathy
AZD2693	NASH resolution		non-alcoholic steatohepatitis
AZD3366	CD39L3		cardiovascular disease
AZD3427	Relaxin ThP		cardiovascular disease
AZD5462	Relaxin mimetic		cardiovascular disease
AZD7503	ASO		non-alcoholic steatohepatitis
MEDI8367	avb8		chronic kidney disease
Respiratory & Immunology			
AZD4604	Inhaled JAK1 inhibitor		asthma
AZD5055	Porcupine inhibitor		idiopathic pulmonary fibrosis
AZD8630	Inhaled TSLP mAb		asthma
Rare Disease			
ALXN1720	anti-C5 bispecific minibody		generalised myasthenia gravis
ALXN1820	anti-properdin bispecific		haematology
ALXN1850	next-generation asfotase alfa		hypophosphatasia
Other			
AZD4041	orexin 1 receptor antagonist		opioid use disorder
MEDI0618	PAR2 antagonist mAb		osteoarthritis pain
MEDI1341	alpha synuclein mAb		Parkinson's disease
MEDI1814	amyloid beta mAb		Alzheimer's disease

Phase II

Compound	Mechanism		Area Under Investigation
Oncology			
adavosertib	Wee1 inhibitor		ovarian cancer, solid tumours, uterine serous cancer
AZD0171 + <i>Imfinzi</i> + CTx	anti-LIF mAb + PD-L1 mAb + CTx		1L metastatic pancreatic ductal adenocarcinoma
AZD4573 + <i>Calquence</i>	CDK9 inhibitor + BTK inhibitor		haematological malignancies
AZD5305	PARP1Sel		solid tumours
camizestrant	selective oestrogen receptor degrader		oestrogen receptor +ve breast cancer
capiwasertib	AKT inhibitor		prostate cancer
cerlasertib	ATR inhibitor		solid tumours
<i>Imfinzi</i> (platform) COAST	PD-L1 mAb + multiple novel oncology therapies		non-small cell lung cancer
<i>Imfinzi</i> (platform) HUDSON	PD-L1 mAb + multiple novel oncology therapies		post IO non-small cell lung cancer
<i>Imfinzi</i> (platform) NeoCOAST	PD-L1 mAb + multiple novel oncology therapies		non-small cell lung cancer

Development Pipeline

continued

Phase II continued

Compound	Mechanism	Area Under Investigation
<i>Imfinzi</i> + FOLFOX + bevacizumab COLUMBIA 1	PD-L1 mAb + CTx + VEGF	1st-line metastatic microsatellite-stable colorectal cancer
<i>Imfinzi</i> + <i>Lynparza</i> ORION	PD-L1 mAb + PARP inhibitor	PP 1st-line metastatic non-small cell lung cancer
<i>Imfinzi</i> + monalizumab	PD-L1 mAb + NKG2a mAb	PP solid tumours
MEDI5752	PD-1/CTLA-4 bispecific mAb	solid tumours
oleclumab + CTx or <i>Imfinzi</i> + oleclumab + CTx	CD73 mAb + CTx or PD-L1 mAb + CD73 mAb + CTx	metastatic pancreatic cancer
Post-1L <i>Tagrisso</i> (platform) ORCHARD	EGFR inhibitor + multiple novel oncology therapies	EGFRm non-small cell lung cancer
<i>Tagrisso</i> + savolitinib SAVANNAH	EGFR inhibitor + MET inhibitor	PP advanced EGFRm non-small cell lung cancer
CVRM		
AZD4831	myeloperoxidase	heart failure with a preserved ejection fraction
AZD5718	FLAP	coronary artery disease/chronic kidney disease
AZD8233	hypercholesterolemia	cardiovascular disease
AZD8601	VEGF-A	PP cardiovascular disease
AZD9977 + <i>Farxiga/Forxiga</i> cotadutide	MR modulator + SGLT2 inhibitor GLP-1/glucagon dual agonist	heart failure with chronic kidney disease type-2 diabetes, obesity and NASH, diabetic kidney disease
MEDI6570	LOX-1 mAb	cardiovascular disease
tozorakimab	IL-33 mAb	diabetic kidney disease
zibotentan + <i>Farxiga/Forxiga</i> ZENITH-CKD	ETA antagonist + SGLT2	chronic kidney disease
Respiratory & Immunology		
AZD1402	Inhaled IL-4Ra	PP asthma
AZD7986	DPP1	PP chronic obstructive pulmonary disease
brazikumab EXPEDITION	IL-23 mAb	ulcerative colitis
navafenterol	MABA	PP chronic obstructive pulmonary disease
tozorakimab	IL-33 mAb	COPD/atopic dermatitis/asthma/COVID-19
Rare Disease		
ALXN2050	oral factor D inhibitor	paroxysmal nocturnal haemoglobinuria
danicopan (ALXN2040)	factor D inhibitor	geographic atrophy
Other		
MEDI7352	NGF/TNF bispecific mAb	osteoarthritis pain and painful diabetic neuropathy

Phase III/Pivotal Phase II/Registration (listed until launched in all applicable major regions)

Compound	Mechanism	Area Under Investigation	Additional information	Estimated Filing Acceptance			
				US	EU	Japan	China
Oncology							
camizestrant + CDK4/6 SERENA-6	selective oestrogen receptor degrader + CDK4/6 inhibitors	1L HR+ HER2- ESR1m breast cancer		2023+	2023+	2023+	
camizestrant + palbociclib SERENA-4	selective oestrogen receptor degrader + CDK4/6 inhibitor	1st-line HR+ HER2- breast cancer		2023+	2023+	2023+	2023+
capivasertib + abiraterone CAPItello-281	AKT inhibitor + abiraterone	PTEN deficient metastatic hormone sensitive prostate cancer	PP	2023+	2023+	2023+	2023+
capivasertib + CTx CAPItello-290	AKT inhibitor + CTx	1st-line metastatic triple negative breast cancer	PP	2023	2023	2023	2023+
capivasertib + fulvestrant CAPItello-291	AKT inhibitor + fulvestrant	2nd-line and beyond in AI resistant locally advanced (inoperable) or metastatic breast cancer	PP	2023	2023	2023	2023+
capivasertib + fulvestrant + palbociclib CAPItello-292	AKT inhibitor + fulvestrant + CDK4/6 inhibitor	1st-line triplet in early relapse/ET resistant locally advanced (inoperable) or metastatic breast cancer	PP	2023+	2023+	2023+	2023+
datopotamab deruxtecan TROPION-Lung01	TROP2 targeting antibody drug conjugate	2L+ NSCLC without actionable genomic mutations	PP	2023	2023	2023	2023+
datopotamab deruxtecan# TROPION-Breast01	TROP-2 targeting antibody drug conjugate	2-3L HR+ HER2- breast cancer	PP	2023+	2023+	2023+	2023+

Development Pipeline

continued

Phase III/Pivotal Phase II/Registration (listed until launched in all applicable major regions) continued

Compound	Mechanism	Area Under Investigation	Additional information	Estimated Filing Acceptance			
				US	EU	Japan	China
<i>Imfinzi</i> +/- tremelimumab + CTX POSEIDON	PD-L1 mAb +/- CTLA-4 mAb + CTX	1st-line non-small cell lung cancer	PP	Accepted	Accepted	Submitted	2023+
<i>Imfinzi</i> + tremelimumab HIMALAYA	PD-L1 mAb + CTLA-4 mAb	1st-line hepatocellular carcinoma	PP	H1 2022 (Orphan Drug Designation)	H1 2022 (Orphan designation)	H1 2022	2023+
<i>Imfinzi</i> + tremelimumab + SoC NILE	PL-L1 mAb + CTLA-4 mAb + SoC	1st-line urothelial cancer	PP	2023	2023	2023	2023+
<i>Imfinzi</i> +/- tremelimumab + CRT ADRIATIC	PD-L1 mAb +/- CTLA-4 mAb + CRT	1st-line limited-stage small-cell lung cancer	PP	2023	2023	2023	2023
<i>Koselugo</i> / selumetinib SPRINT	MEK inhibitor	paediatric neurofibromatosis type-1	PP	Launched (Priority Review, Breakthrough Therapy, Orphan Drug Designation)	Launched (Breakthrough Therapy, Orphan designation)	Submitted (Orphan Drug)	H2 2022
<i>Lynparza</i> + <i>Imfinzi</i> + bevacizumab DuO-O	PARP inhibitor + PD-L1 mAb + VEGF inhibitor	1st-line ovarian cancer	PP	2023+	2023+	2023+	2023+
<i>Lynparza</i> + <i>Imfinzi</i> DuO-E	PARP inhibitor + PD-L1 mAb	1st-line endometrial cancer	PP	2023+	2023+	2023+	2023+
monalizumab + cetuximab INTERLINK-1	NKG2a mAb + EGFR mAb	2L+ relapsed metastatic head and neck squamous cell cancer	PP	2023+	2023+	2023+	N/A
savolitinib + <i>Imfinzi</i> SAMETA	MET inhibitor + PD-L1 mAb	1st-line papillary renal cell carcinoma	PP	2023+	2023+		2023+
CVRM							
eplontersen	ligand-conjugated antisense	patients with hereditary transthyretin-mediated amyloid polyneuropathy	PP	H2 2022 (Orphan Drug Designation)			
eplontersen	ligand-conjugated antisense	patients with hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy	PP	2023+ (Orphan Drug Designation)	2023+		
roxadustat OLYMPUS ROCKIES	hypoxia-inducible factor prolyl hydroxylase inhibitor	anaemia in chronic kidney disease/end-stage renal disease	PP				Launched
Respiratory & Immunology							
brazikumab INTREPID	IL-23 mAb	Crohn's disease		2023+	2023+	2023+	2023+
<i>Fasenra</i> CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE	IL-5R mAb	severe uncontrolled asthma	PP	Launched	Launched	Launched	2023
PT027	ICS/SABA	asthma	PP	H1 2022			
<i>Saphnelo</i> TULIP 1 & TULIP 2 AZALEA (China)	Type I IFN receptor mAb	systemic lupus erythematosus	PP	Launched (Fast Track, Orphan Drug Designation)	Accepted	Launched	2023+
<i>Tezspire</i> (tezepelumab) NAVIGATOR DIRECTION	TSLP mAb	severe uncontrolled asthma	PP	Launched (Priority Review)	Accepted	Accepted	2023+
Rare Disease							
acoramidis (ALXN2060)	oral TTR stabilizer	transthyretin amyloid cardiomyopathy	PP				2023
ALXN1840	bis-choline tetra-thiomolybdate	Wilson disease		H2 2022 (Orphan Drug Designation)	H2 2022 (Orphan designation)	H2 2022	
CAEL-101	fibril-reactive mAb	AL amyloidosis		2023+ (Fast Track, Orphan Drug Designation)	2023+ (Orphan designation)	2023+	
danicopan (ALXN2040)	factor D inhibitor	paroxysmal nocturnal haemoglobinuria with extravascular haemolysis		2023 (Orphan Drug Designation)	2023 (Orphan designation)	2023	

Development Pipeline

continued

Phase III/Pivotal Phase II/Registration (listed until launched in all applicable major regions) continued

Compound	Mechanism	Area Under Investigation	Additional information	Estimated Filing Acceptance			
				US	EU	Japan	China
Other and COVID-19							
Evusheld (AZD7442)	COVID-19 LAAB combination	prevention and treatment of COVID-19	Prophylaxis FDA Emergency Use Authorisation submission approved	Approved (Emergency Use)	H1 2022	H1 2022	H2 2022
nirsevimab	RSV mAb-YTE	passive RSV immunisation	PP	H2 2022 (Fast Track Designation, Breakthrough Therapy Designation)	H1 2022 (PRIME)	2023	2023 (Breakthrough Therapy Designation)
Vaxzevria	SARS-CoV-2	COVID vaccine	PP EMA and Japan Conditional Marketing Authorisation	H1 2022	Launched	Launched	

Significant Life-cycle Management

Regulatory submission dates shown for assets in Phase III and beyond. Projects in Phase III unless otherwise noted.

Compound	Mechanism	Area Under Investigation	Additional information	Estimated Filing Acceptance			
				US	EU	Japan	China
Oncology							
Calquence ASCEND	BTK inhibitor	relapsed/refractory chronic lymphocytic leukaemia	PP	Launched (Breakthrough Therapy, Orphan Drug Designation)	Launched	Launched	2023
Calquence ELEVATE-TN	BTK inhibitor	1st-line chronic lymphocytic leukaemia	PP	Launched (Breakthrough Therapy, Orphan Drug Designation)	Launched	H2 2022	2023+
Calquence + R-CHOP ESCALADE	BTK inhibitor + R-CHOP	1st-line diffuse large B cell lymphoma		2023+	2023+	2023+	2023+
Calquence + venetoclax + obinutuzumab AMPLIFY	BTK inhibitor + BCL-2 inhibitor + anti-CD20 mAb	1st-line chronic lymphocytic leukaemia	PP	2023+	2023+	N/A	2023+
Calquence ECHO	BTK inhibitor	1st-line mantle cell lymphoma	PP	2023 (Orphan Drug Designation)	2023	2023	2023+
Enhertu DESTINY-Breast02	HER2 targeting antibody drug conjugate	HER2-positive, unresectable and/or metastatic breast cancer pre-treated with prior standard of care HER2 therapies, including T-DM1	PP	H2 2022	H2 2022	N/A	N/A
Enhertu DESTINY-Breast03	HER2 targeting antibody drug conjugate	HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane	PP	Accepted (Breakthrough Therapy Designation, Priority Review)	Accepted	Submitted	H1 2022
Enhertu DESTINY-Breast04	HER2 targeting antibody drug conjugate	HER2-low, unresectable and/or metastatic breast cancer subjects	PP	H1 2022	H1 2022	H1 2022	H2 2022
Enhertu DESTINY-Breast05	HER2 targeting antibody drug conjugate	HER2-positive post-neoadjuvant high-risk breast cancer	PP	2023+	2023+	2023+	
Enhertu DESTINY-Breast06	HER2 targeting antibody drug conjugate	post-ET HER2-low/HR+ breast cancer 2L	PP	2023+	2023+	2023+	2023+
Enhertu (platform) DESTINY-Breast07	HER2 targeting antibody drug conjugate	HER2+ breast cancer	PP	Phase II			
Enhertu (platform) DESTINY-Breast08	HER2 targeting antibody drug conjugate	HER2-low breast cancer	PP	Phase I			
Enhertu DESTINY-Breast09	HER2 targeting antibody drug conjugate	1st-line HER2-positive breast cancer	PP	2023+	2023+	2023+	2023+
Enhertu DESTINY-Breast11	HER2 targeting antibody drug conjugate	neoadjuvant HER2-positive breast cancer	PP				

Development Pipeline

continued

Significant Life-cycle Management continued

Compound	Mechanism	Area Under Investigation	Additional information	Estimated Filing Acceptance			
				US	EU	Japan	China
<i>Enhertu</i> DESTINY-Gastric01	HER2 targeting antibody drug conjugate	HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens	PP Phase II. EU submission includes data from Gastric02	Approved (Priority Review, Breakthrough Therapy, Orphan Drug Designation)	Accepted	Approved	2023+
<i>Enhertu</i> DESTINY-Gastric04	HER2 targeting antibody drug conjugate	2nd-line HER2-positive gastric	PP	2023+	2023+	2023+	2023+
<i>Enhertu</i> DESTINY-Lung01	HER2 targeting antibody drug conjugate	HER2-over-expressing or -mutated, unresectable and/or metastatic non-small cell lung cancer	PP Phase II	Breakthrough Therapy Designation			
<i>Enhertu</i> DESTINY-Lung04	HER2 targeting antibody drug conjugate	1st-line non-small cell lung cancer	PP	2023+	2023+	2023+	2023+
<i>Enhertu</i> DESTINY-PanTumour01	HER2 targeting antibody drug conjugate	HER2-expressing solid tumours	PP Phase II				
<i>Enhertu</i> DESTINY-PanTumour02	HER2 targeting antibody drug conjugate	HER2-expressing solid tumours	PP Phase II				
<i>Imfinzi</i> PEARL	PD-L1 mAb	1st-line metastatic non-small cell lung cancer	PP	H2 2022	H2 2022	H2 2022	H2 2022
<i>Imfinzi</i> + CRT PACIFIC-2	PD-L1 mAb + CRT	locally-advanced (Stage III) non-small cell lung cancer	PP	H2 2022	H2 2022	H2 2022	
<i>Imfinzi</i> post-SBRT PACIFIC-4	PD-L1 mAb post-SBRT	Stage I/II non-small cell lung cancer	PP	2023+	2023+	2023+	2023+
<i>Imfinzi</i> + CRT PACIFIC-5 (China)	PD-L1 mAb + CRT	locally-advanced (Stage III) non-small cell lung cancer	PP				2023
<i>Imfinzi</i> + CTx neoadjuvant AEGEAN	PD-L1 mAb + CTx	locally-advanced (Stage II-III) non-small cell lung cancer	PP	2023	2023	2023	2023+
<i>Imfinzi</i> + CTx MERMAID-1	PD-L1 mAb + CTx	Stage II-III adjuvant non-small cell lung cancer		2023+	2023+	2023+	2023+
<i>Imfinzi</i> MERMAID-2	PD-L1 mAb	Stage II-III premetastatic non-small cell lung cancer		2023+	2023+	2023+	2023+
<i>Imfinzi</i> + CRT KUNLUN	PD-L1 mAb + CRT	locally advanced oesophageal squamous cell carcinoma	PP	2023+	2023+	2023+	2023+
<i>Imfinzi</i> + CTx TOPAZ-1	PD-L1 mAb + CTx	1st-line biliary tract cancer	PP	H1 2022 (Orphan Drug Designation)	H1 2022	H1 2022	H1 2022
<i>Imfinzi</i> + FLOT MATTERHORN	PD-L1 mAb + CTx	neo-adjuvant/adjuvant gastric cancer	PP	2023+	2023+	2023+	2023+
<i>Imfinzi</i> + VEGF + TACE EMERALD-1	PD-L1 mAb + VEGF + TACE	locoregional hepatocellular carcinoma	PP	H2 2022	H2 2022	H2 2022	2023
<i>Imfinzi</i> + VEGF EMERALD-2	PD-L1 mAb + VEGF	adjuvant hepatocellular carcinoma	PP	2023	2023	2023	2023
<i>Imfinzi</i> CALLA	PD-L1 mAb	locally-advanced cervical cancer	PP	H2 2022	H2 2022	H2 2022	H2 2022
<i>Imfinzi</i> + CTx NIAGARA	PD-L1 mAb + CTx	muscle invasive bladder cancer	PP	2023	2023	2023	N/A
<i>Imfinzi</i> + EV +/- treme VOLGA	PD-L1 + nectin-4 targeting antibody drug conjugate +/- CTLA4	muscle invasive bladder cancer		2023+	2023+	2023+	N/A
<i>Imfinzi</i> POTOMAC	PD-L1 mAb	non muscle invasive bladder cancer	PP	2023+	2023+	2023+	N/A
<i>Imfinzi</i> (platform) MAGELLAN	PD-L1 mAb + multiple novel oncology therapies +/- CTx	1st-line metastatic non-small cell lung cancer	PP Phase II				
<i>Imfinzi</i> (platform) BEGONIA	PD-L1 mAb with paclitaxel and multiple novel oncology therapies	1st-line metastatic triple negative breast cancer	PP Phase II				
<i>Lynparza</i> OlympiA	PARP inhibitor	germline breast cancer gene adjuvant breast cancer	PP	Accepted (Priority Review)	Accepted	Submitted (Orphan Drug Designation)	2023
<i>Lynparza</i> (basket) MK-7339-002/ LYNK002	PARP inhibitor	homologous recombination repair gene mutation	PP Phase II				

Development Pipeline

continued

Significant Life-cycle Management *continued*

Compound	Mechanism	Area Under Investigation	Additional information	Estimated Filing Acceptance			
				US	EU	Japan	China
<i>Lynparza</i> + abiraterone PROpel	PARP inhibitor + NHA	prostate cancer	PP	H1 2022	Accepted	H1 2022	2023+
<i>Lynparza</i> LYNK-003	PARP inhibitor	platinum sensitive 1st-line colorectal cancer	PP	2023	2023	2023	2023
<i>Lynparza</i> # MONO-OLA1	PARP inhibitor	1st-line breast cancer gene wild-type ovarian cancer	PP	2023+	2023+	2023+	2023+
<i>Tagrisso</i> LAURA	EGFR inhibitor	Stage III EGFRm non-small cell lung cancer		2023	2023	2023	2023
<i>Tagrisso</i> + CTx FLAURA2	EGFR inhibitor + CTx	1st-line advanced EGFRm non-small cell lung cancer		2023	2023		2023+
<i>Tagrisso</i> +/- CTx neoadjuvant NeoADAURA	EGFR inhibitor +/- CTx	Stage II/III resectable EGFRm NSCLC		2023+	2023+	2023+	2023+
<i>Tagrisso</i> ADAURA	EGFR inhibitor	adjuvant EGFRm non-small cell lung cancer		Launched (Breakthrough Therapy Designation, Priority Review)	Approved	Submitted	Launched
CVRM							
<i>Brilinta/Brilique</i> THALES	P2Y12 receptor antagonist	acute ischaemic stroke or transient ischaemic attack		Launched		N/A	Accepted
<i>Bydureon BCise</i> (autoinjector)	GLP-1 receptor agonist	type-2 diabetes		Launched	Launched	N/A	H2 2022
<i>Farxiga/Forxiga</i> DAPA-CKD	SGLT-2 inhibitor	renal outcomes and cardiovascular mortality in patients with chronic kidney disease		Launched (Fast Track Breakthrough Therapy Designation)	Launched	Launched (Priority Review)	Accepted
<i>Farxiga/Forxiga</i> DAPA-MI	SGLT-2 inhibitor	prevention of heart failure and cardiovascular (CV) death following a myocardial infarction		2023+	2023+	N/A	N/A
<i>Farxiga/Forxiga</i> DELIVER	SGLT-2 inhibitor	worsening heart failure or CV death in patients with chronic heart failure (HFpEF)		H2 2022	H2 2022	H2 2022	H2 2022
<i>Lokelma</i> DIALIZE-Outcomes	potassium binder	CV outcomes in patients on chronic haemodialysis with hyperkalaemia		2023+ (Fast Track)	2023+	N/A	2023+
<i>Lokelma</i> STABILIZE-CKD	potassium binder	hyperkalaemia in chronic kidney disease		2023+	2023+	2023+	2023+
roxadustat	hypoxia-inducible factor prolyl hydroxylase inhibitor	anaemia in myelodysplastic syndrome	PP	2023+			2023+
roxadustat	hypoxia-inducible factor prolyl hydroxylase inhibitor	chemotherapy induced anaemia	PP	Phase II			
<i>Xigduo XR/Xigduo</i>	SGLT-2 inhibitor/ metformin FDC	type-2 diabetes		Launched	Launched		H1 2022
Respiratory & Immunology							
<i>Breztri/Trixeo</i> (PT010) KALOS LAGOS	LABA/LAMA/ ICS	asthma		2023+	2023+	2023+	2023+
<i>Fasenra</i> RESOLUTE	IL-5R mAb	chronic obstructive pulmonary disease	PP	2023+		2023+	2023+
<i>Fasenra</i> ARROYO	IL-5R mAb	chronic spontaneous urticaria		Phase II			
<i>Fasenra</i> FJORD	IL-5R mAb	bullous pemphigoid		2023+	2023+	2023+	2023+
<i>Fasenra</i> HILLIER	IL-5R mAb	atopic dermatitis		Phase II			
<i>Fasenra</i> MAHALE	IL-5R mAb	non-cystic fibrosis bronchiectasis		2023+	2023+		2023+
<i>Fasenra</i> MANDARA	IL-5R mAb	eosinophilic granulomatosis with polyangiitis		2023	2023	2023	2023+
<i>Fasenra</i> MESSINA	IL-5R mAb	eosinophilic esophagitis		2023	2023	2023	
<i>Fasenra</i> NATRON	IL-5R mAb	hypereosinophilic syndrome		2023	2023	2023	2023+
<i>Fasenra</i> OSTRO ORCHID (China/ Japan)	IL-5R mAb	nasal polyps	PP	Accepted		2023+	2023+
<i>Saphnelo</i>	Type I IFN receptor mAb	lupus nephritis	PP	Phase II			

Development Pipeline

continued

Significant Life-cycle Management *continued*

Compound	Mechanism	Area Under Investigation	Additional information	Estimated Filing Acceptance			
				US	EU	Japan	China
<i>Saphnelo</i> TULIP-SC	Type I IFN receptor mAb	systemic lupus erythematosus (subcutaneous)	PP	2023+	2023+	2023+	
<i>Tezspire</i> (tezepelumab)	TSLP mAb	chronic obstructive pulmonary disease	PP Phase II				
<i>Tezspire</i> (tezepelumab) WAYPOINT	TSLP mAb	nasal polyps	PP	2023+	2023+	2023+	2023+
Rare Disease							
<i>Andexxa</i> (ALXN2070)	anti-factor Xa reversal	urgent surgery	Phase II				
<i>Andexxa</i> (ALXN2070)	anti-factor Xa reversal	acute major bleed		Launched (Accelerated approval)	Launched	Accepted (Orphan drug)	
<i>Ultomiris</i> (ALXN1210)	anti-complement C5 mAb	dermatomyositis	Phase II/III				
<i>Ultomiris</i> (ALXN1210)	anti-complement C5 mAb	generalised myasthenia gravis		Accepted (Priority Review)	Accepted	Accepted	
<i>Ultomiris</i> (ALXN1210)	anti-complement C5 mAb	neuromyelitis optica spectrum disorder		H2 2022	H2 2022	H2 2022	
<i>Ultomiris</i> (ALXN1210)	anti-complement C5 mAb	haematopoietic stem cell transplant-associated thrombotic microangiopathy		2023+ (Orphan Drug Designation)	2023+	2023+	
<i>Ultomiris</i> (ALXN1210)	anti-complement C5 mAb	subcutaneous, paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome		Accepted (Orphan Drug Designation)	H1 2022		
<i>Ultomiris</i> (ALXN1210)	anti-complement C5 mAb	complement-mediated thrombotic microangiopathy		2023+		2023+	